A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

NCT03574571 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

732

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Docetaxel 75 mg/m2
DRUG: Docetaxel 60 mg/m2
DRUG: Radium-223

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]